omniture
信达生物

Latest News

Two Clinical Studies with IBI301, a Biosimilar Candidate to Rituximab, Met Primary Endpoints

SUZHOU, China, May 8, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801) and El...

2019-05-08 08:00 6451

Innovent Announces First Patient Dosed in Phase I Clinical Trial of IBI318 Bispecific Antibody in China

SUZHOU, China, April 24, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a ...

2019-04-24 07:21 1711

Innovent Announces First Patient Dosed in a Phase I Clinical Trial of IBI302 for the Treatment of Wet AMD

SUZHOU, China, April 18, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a ...

2019-04-18 08:10 4079

Innovent Receives 10th Anniversary CHIC IPO of the Year Award

SHANGHAI, March 28, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world...

2019-03-28 08:00 2776

Innovent Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody

SUZHOU, China, March 21, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a ...

2019-03-21 07:21 910

Innovent Announces First Patient Dosed in a Phase IIa Clinical Study of IBI306, an Anti-PCSK9 Monoclonal Antibody

SUZHOU, China, March 20, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a ...

2019-03-21 07:20 552

Innovent Announces First Patient Dosed in Phase I Clinical Trial of Anti-CD47 Monoclonal Antibody in the U.S.

SUZHOU, China, March 19, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a ...

2019-03-19 08:09 4365

Innovent Announces 2018 Annual Results

HONG KONG, March 14, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a worl...

2019-03-14 07:36 1394

First Patient Dosed in a Clinical Trial of Tyvyt® (Sintilimab injection) in Combination with IBI305 as First Line Treatment for Patients with Advanced Hepatocellular Carcinoma

SUZHOU, China, Feb. 28, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801) toda...

2019-02-28 08:30 2695

Innovent Receives IFR Asia-Pacific IPO of the Year 2018 and IFR Asia Review Hong Kong Equity Issue of the Year 2018 Awards

HONG KONG, Feb. 27, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), today a...

2019-02-27 12:00 777

Innovent Organized a Forum Discussing the Pending Launch of its Anti PD-1 Tyvyt® (Sintilimab injection) as Part of the National Mega Innovation Program in Beijing

BEIJING, Feb. 22, 2019 /PRNewswire/ -- The Forum for the National Mega Innovation Program in conjun...

2019-02-22 15:02 1257

Innovent Announces a Collaboration with Chipscreen Biosciences to Evaluate the Combination Therapy in Colorectal Cancer Patients

SUZHOU, China, Feb. 18, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a w...

2019-02-18 08:00 4935

Innovent Receives IND Approval of a Bispecific Antibody (IBI318) by the NMPA

SUZHOU, China, Feb. 7, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a wo...

2019-02-07 22:37 3337

NMPA Accepts New Drug Application for IBI-305, a Biosimilar Product Candidate of Bevacizumab (Avastin®)

SUZHOU, China, Jan. 28, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a w...

2019-01-29 12:19 970

Innovent Announces First Patient Dosed in a Phase I Clinical Trial of Anti-CD47 Monoclonal Antibody

SUZHOU, China, Jan. 15, 2019 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a w...

2019-01-15 08:00 947

China's NMPA Approves Innovent's Anti-PD-1 Antibody Tyvyt® (Sintilimab injection) for Hodgkin's Lymphoma

SUZHOU, China, Dec. 27, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801) and...

2018-12-27 16:45 2095

Innovent Announces Two Clinical Studies with the Anti-VEGF Monoclonal Antibody IBI305, a Biosimilar Candidate to Avastin (Bevacizumab), Met Primary Endpoints

SUZHOU, China, Dec. 12, 2018 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a...

2018-12-13 08:00 358
12